

Dear Editor,

Please find attached a revised version of our manuscript “Serum HER2 as a predictive biomarker for tissue HER2 status and for prognosis in patients with gastric cancer”, which we would like to resubmit for publication in *World Journal of Gastroenterology*.

Your comments and those of the reviewers were highly insightful and enabled us to greatly improve the quality of our manuscript. In the following pages are our point-by-point responses to each of the comments of the reviewers.

We tried our best to improve the manuscript and made some changes in the manuscript. These changes will not influence the content and framework of the paper. We appreciate for Editor/Reviewers’ warm work earnestly, and hope that the revisions in the manuscript and our accompanying responses will be sufficient to make our manuscript suitable for publication in the eminent journal.

We shall look forward to hearing from you at your earliest convenience.

Yours sincerely,

Lin Chen
Department of General Surgery
Chinese People’s Liberation Army General Hospital
28 Fuxing Road, Beijing 100853, China
Tel: +86-10-66938128
Fax: +86-10-68181689

Comments to the Authors:

Reviewer code: 00068348

1. *Serum HER2 plays a crucial role in prognosis for patients with breast, biliary and gastric cancer. It is important also as a prognostic marker of gastric cancer recurrence and indicates response to therapeutic maneuvers. The article deals with a very interesting field of gastric cancer. The number of patients in such a short period of time is beneficial. Did all these patients had adenocarcinomas? The location of the tumor and the operation performed i believe they could be mentioned. Also the type of surgery and lymph node involment do they affect the results? The whole set up of the study is very good and the results contribute to medical knowledge.*

Response: Thanks for reviewer's positive comments. All tumors were adenocarcinomas, which have been added in the revised manuscript (**Results** part). We have also added information regarding tumor location, operation, type of surgery and lymph node involvement in **Table 3**. None of these had impact on the results.

Reviewer code: 02520549

1. *The manuscript is very interesting, and it has several important new on gastric cancer therapy. It is of particular notice the use of Serum HER2 as a predictive biomarker for tissue HER2 status and prognosis, which seems a potential new tool to improve the treatment of gastric cancer.*

Response: Thanks for reviewer's positive comments.